Pennsylvania Senate Resolution 359 designates September 2026 as "Veteran Suicide Prevention and Awareness Month" to highlight the elevated suicide rates among military veterans in the state. The resolution cites specific statistics, noting that nearly 250 Pennsylvania veterans die by suicide annually and that female veterans face a significantly higher risk than their male counterparts. It acknowledges contributing factors such as post-traumatic stress disorder, unemployment, and difficulties reintegrating into civilian life. Additionally, the bill expresses support for the Department of Military and Veterans Affairs and its ongoing initiatives to provide resources and education on suicide prevention for veterans and their families.
This resolution designates August 2026 as Appendix Cancer Awareness Month in Pennsylvania, aiming to increase public knowledge of this rare disease. The bill highlights that appendix cancer is often difficult to diagnose early due to vague symptoms and its rarity, which can lead to delayed treatment. It encourages residents to support early detection efforts and research initiatives led by organizations like the Appendix Cancer PMP Research Foundation.
Pennsylvania Senate Resolution 358 officially designates September 2026 as Suicide Prevention Month within the state. The resolution cites national and local statistics regarding suicide rates and mental health challenges to support this designation. It aims to raise public awareness, encourage open dialogue about mental health, and promote community engagement during the designated month.
Pennsylvania Senate Bill 1430 amends state criminal law to allow owners, operators, and employees of health care facilities to use nonviolent means to deny entry to law enforcement officers on their premises. This protection applies unless the officer can demonstrate probable cause that a specific individual is present and physically possesses a judicial warrant clearly identifying that person as the subject of the order. The bill defines key terms such as "health care facility" and "judicial warrant," limiting the scope of this exception to written orders from federal or state courts. If enacted, the law would take effect 60 days after its passage.
Pennsylvania House Bill 2749 amends the state's Controlled Substance, Drug, Device and Cosmetic Act to expand legal protections for individuals and entities involved in responding to opioid overdoses. The bill grants immunity from criminal prosecution, civil liability, and professional disciplinary action to licensed health care professionals who prescribe or dispense opioid antagonists, including naloxone, as long as they act in good faith. It also extends similar protections to first responders, law enforcement, and private citizens who administer these medications to people they believe are suffering an overdose. Additionally, the legislation allows municipalities, local health departments, and community organizations to distribute expired opioid antagonists without facing legal liability, provided the medication is less than five years past its expiration date.
Pennsylvania House Bill 2731 directs the Department of Drug and Alcohol Programs to work with the Department of General Services to procure opioid antagonists through a competitive process. The bill mandates that cost-effectiveness must account for at least 90% of the decision-making weight, while also considering product efficacy, availability, brand type, and shelf life. Additionally, it requires the department to submit an annual report on the procurement strategy and vendor selection to legislative committee leaders starting in 2028.
Pennsylvania House Bill 2734 requires health insurance companies to cover FDA-approved diagnostic tests and treatments that slow the progression of Alzheimer's disease and related dementias. The mandate applies to insurers offering individual or group health policies in the state, with a compliance deadline of January 1, 2028, unless federal law preempts the requirement. The bill explicitly prohibits insurers from using step therapy for these specific treatments, meaning patients cannot be forced to try other medications first before receiving coverage for approved Alzheimer's therapies.
HB 2745 authorizes Pennsylvania to join the Interstate Podiatric Medical Licensure Compact, a multi-state agreement that creates a streamlined process for podiatric physicians to obtain licenses in multiple states. The bill establishes an interstate commission to administer the compact, manage a shared database of licensure and disciplinary records, and coordinate joint investigations among member states. Eligible podiatrists must designate a primary state of license and meet specific criteria, including a clean criminal record and no prior license discipline, to receive expedited multi-state licenses. The legislation also outlines procedures for renewing these licenses, handling disciplinary actions across state lines, and the financial responsibilities of participating states.
Pennsylvania House Bill 2733, known as the Banked Use for Maternity Protection Act, requires employers to provide eligible employees with a dedicated account containing 24 hours of paid leave specifically for prenatal medical appointments and related travel. To qualify, an employee must have worked for the same employer in the Commonwealth for at least 30 days, after which the employer must establish this separate account within two days of notification. The bill mandates that this leave be compensated at the employee's regular rate and count toward seniority and benefits, while prohibiting employers from forcing staff to use other types of leave or retaliating against them for utilizing these protections. Employers with 15 or fewer employees may apply for a six-month hardship exemption, and violations of the act are subject to fines of up to $50,000 per instance.
Pennsylvania Senate Bill 1424 amends the state's Newborn Child Testing Act to officially add Gaucher disease to the list of conditions covered by the newborn screening and follow-up program. The bill directs the relevant health department, with approval from a technical advisory board, to include this specific genetic disorder in routine infant testing. This change aims to help healthcare providers identify the condition early so they can determine if treatment or other services are needed to prevent potential intellectual disability, physical disability, or death.
